Andrew Hong
- SOM: Peds: Solid Tumor
Assistant Professor
- (404) 727-3720
- andrew.hong2@emory.edu
- Laboratory
-
Emory University School of Medicine
Pediatrics
1760 Haygood Drive NE, HSRB 370
Overview
Andrew Hong, MD, joined Childrens Healthcare of Atlanta and Emory University School of Medicine as an Assistant Professor of Pediatrics with an Endowed Invesitgatorship in March 2020. He came to Atlanta, Ga., from Boston, Mass., where he was on the faculty at Dana-Farber/Boston Childrens Cancer and Blood Disorders Center as an instructor of pediatrics.
Prior to being a faculty member, Dr. Hong earned his undergraduate degree from the University of Chicago. He was recruited by McKinsey & Company as a business analyst. After several years, Dr. Hong received a Post-Baccalaureate Intramural Research Training Award from the National Cancer Institute (NCI) to perform yeast genomics under Munira Basrai, PhD, at the Center for Cancer Research. He returned to The University of Chicago Pritzker School of Medicine, where he earned his medical degree. While in medical school, his research focused on studying sirtuins under Raul Mostoslavsky, MD, PhD; David Lombard, PhD; and Frederick Alt, PhD, at Boston Childrens Hospital, studying breast cancer risk under Funmi Olopade, MD, at The University of Chicago.
Dr. Hong completed his pediatrics internship and residency at Boston Childrens Hospital and Boston Medical Center. He then completed a fellowship in pediatric hematology and oncology at the Dana-Farber/Boston Childrens Cancer and Blood Disorders Center. Afterwards, Dr. Hong became an instructor in pediatrics at Harvard Medical School, while also completing his post-doctoral fellowship under William C. Hahn, MD, PhD, at the Dana-Farber/Boston Childrens Cancer and Blood Disorders Center, Broad Institute and Massachusetts Institute of Technology.
Dr. Hong has broad clinical experience across pediatric oncology. His research (thehonglab.org) is focused on high-risk solid tumors (e.g., kidney cancers, soft tissue sarcomas and brain tumors). These cancers represent the areas of greatest need in pediatric oncology. His work uses functional genomic techniques (e.g., RNAi and CRISPR-Cas9) and the latest sequencing technologies (e.g., long-range phased sequencing, scRNAseq and ATACseq) to identify new therapeutics and mechanisms in pediatric cancers.
His work has been funded by several groups, such as the National Cancer Institute (NCI), U.S. Department of Defense, American Cancer Society, American Association for Cancer Research, CureSearch for Childrens Cancer, Alexs Lemonade Stand Foundation and Cure ATRT.
Academic Appointment
- Assistant Professor, Pediatrics, Emory University School of Medicine
- Assistant Professor, Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta
Education
Degrees
- MD from University of Chicago
Research
Publications
-
SMARCB1 missense mutants disrupt SWI/SNF complex stability and remodeling activity.
03/26/2025 Authors: Cooper GW; Lee BP; Kim WJ; Su Y; Chen VZ; Salas E; Yang X; Lintner RE; Piccioni F; Giacomelli AO -
Histone H3E50K remodels chromatin to confer oncogenic activity and support an EMT phenotype.
NAR Cancer Volume: 7 Page(s): zcaf002
03/01/2025 Authors: Sad K; Fawwal DV; Jones CY; Hill EJ; Skinner KT; Adams ML; Lustenberger S; Lee RS; Lohano SV; Elayavalli SR -
Hallmark discoveries in the biology of non-Wilms tumour childhood kidney cancers.
Nat Rev Urol
01/29/2025 Authors: Perotti D; O'Sullivan MJ; Walz AL; Davick J; Al-Saadi R; Benedetti DJ; Brzezinski J; Ciceri S; Cost NG; Dome JS -
Comprehensive structure-function analysis reveals gain- and loss-of-function mechanisms impacting oncogenic KRAS activity.
bioRxiv
10/25/2024 Authors: Kwon JJ; Dilly J; Liu S; Kim E; Bian Y; Dharmaiah S; Tran TH; Kapner KS; Ly SH; Yang X -
Histone H3 E50K mutation confers oncogenic activity and supports an EMT phenotype.
bioRxiv
08/01/2024 Authors: Sad K; Jones CY; Fawwal DV; Hill EJ; Skinner K; Lustenberger S; Lee RS; Elayavalli SR; Farhi J; Lemon LD -
Targeting TRIP13 in favorable histology Wilms tumor with nuclear export inhibitors synergizes with doxorubicin.
Commun Biol Volume: 7 Page(s): 426
04/08/2024 Authors: Mittal K; Cooper GW; Lee BP; Su Y; Skinner KT; Shim J; Jonus HC; Kim WJ; Doshi M; Almanza D -
Hallmark discoveries in the biology of Wilms tumour.
Nat Rev Urol Volume: 21 Page(s): 158 - 180
03/01/2024 Authors: Perotti D; Williams RD; Wegert J; Brzezinski J; Maschietto M; Ciceri S; Gisselsson D; Gadd S; Walz AL; Furtwaengler R -
Genetic and epigenetic features of bilateral Wilms tumor predisposition in patients from the Children's Oncology Group AREN18B5-Q.
Nat Commun Volume: 14 Page(s): 8006
12/18/2023 Authors: Murphy AJ; Cheng C; Williams J; Shaw TI; Pinto EM; Dieseldorff-Jones K; Brzezinski J; Renfro LA; Tornwall B; Huff V -
Children's Oncology Group's 2023 blueprint for research: Renal tumors.
Pediatr Blood Cancer Volume: 70 Suppl 6 Page(s): e30586
09/01/2023 Authors: Geller JI; Hong AL; Vallance KL; Evageliou N; Aldrink JH; Cost NG; Treece AL; Renfro LA; Mullen EA; COG Renal Tumor Committee -
Genetics of ABCB1 in Cancer.
Cancers (Basel) Volume: 15
08/24/2023 Authors: Skinner KT; Palkar AM; Hong AL